Table IV.

Recognition of the modified peptides by CTL clone 5a

Target Cells Pulsed with PeptidesGM-CSF Release (pg/ml) by CTL Clone 5
Expt. 1 (1510EBV)Expt. 2 (586EBV)
1510EBV+ AGAARASGPGGGAPR728532
1510EBV+ GAARASGPGGGAPR659678
1510EBV+ AARASGPGGGAPR844738
1510EBV+ ARASGPGGGAPR840738
1510EBV+ RASGPGGGAPR851708
1510EBV+ SGPGGGAPR<50<50
1510EBV+ GPGGGAPR<50<50
1510EBV+ ASGPGGGAPRG<50<50
1510EBV+ SGPGGGAPRG<50<50
1510EBV+ ASGPGGGAPR10971044
1510EBV+ AAGPGGGAPR688676
1510EBV + AIGPGGGAPR428550
1510EBV + ALGPGGGAPR200378
1510EBV + AVGPGGGAPR556512
1510EBV + ATGPGGGAPR16301158
1510EBV + ASGPGGGAPK<50<50
1510EBV + ASGPGGGAPH<50<50
1510EBV + TSGPGGGAPR320346
1510EBV + VSGPGGGAPR825666
1510EBV + LSGPGGGAPR<50<50
1510EBV + RSGPGGGAPR<50<50
1510EBV + None<50<50
  • a 586EBV or 1510EBV B cells were incubated with individual peptides at a concentration of 0.1 μg/ml for 90 min. GM-CSF release was measured after coincubation of peptide-loaded EBV cells with 5 × 104 CTL clone 5. The wild-type 10-mer ESO10–53 peptide is underlined. Peptides with amino acid substitution are marked by bold face and underlines. 586EBV and 1510EBV are HLA-A31-positive EBV-transformed B cell lines.